FN2 Earnings Intelligence

United Therapeutics Corporation earnings overview

Latest United Therapeutics Corporation (UTHR) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.

Next reportUnited Therapeutics Corporation reports Wednesday, Nov 4, 2026 · Before market openConsensus EPS $6.01 · consensus revenue $781.1M
UTHR FY2026 Q3 · Calendar Q4 2026

United Therapeutics Corporation

The supplied call analysis points to commercial momentum in Tyvaso and a broader pipeline as the main supports for United Therapeutics’ outlook. That case is balanced by a delayed soft-mist inhaler filing and execution risks tied to regulatory, manufacturing, and patient-switch dynamics.

EPS surprise—
Market move+0.6%

Get the UTHR recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.